Page 2 - Holcombee Grier News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Posted on
370
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer, today announced the appointment of Charles N. York II as chief operating and financial officer and the addition of Natalie Holles to the Company’s board of directors.
“Charles and Natalie are accomplished biopharmaceutical executives and bring significant financial, operational and corporate development expertise to Day One,” said Jeremy Bender, Ph.D., chief executive officer of Day One. “This expansion of our management team and board comes at an exciting time for the Company and follows the recent completion of our Series B financing, as well as the initiation of the pivotal FIREFLY-1 study with DAY101 in pediatric low-grade glioma. Charles and Natalie’s collective skill set will be an asset to Day One as we continue to ....

United States , Dan Budwick , Natalie Holles , Aeglea Biotherapeutics , Jenniferw Mack , Jeremy Bender , Holcombee Grier , Mccombs School Of Business , University Of Connecticut , University Of Texas At Austin , University Of Colorado , Stanford University , Howard Hughes Medical Institute , Day One Biopharmaceuticals , Day One , Chief Operating , Bridgepoint Consulting , Mccombs School , Audentes Therapeutics , Hyperion Therapeutics , Horizon Pharma , One Biopharmaceuticals , South San Francisco , Clinical Oncology , ஒன்றுபட்டது மாநிலங்களில் , ஜெர்மி பெண்டர் ,